Lu Xu1, Xin-Hua Xu2, Cheng Yuan3, Jia-Yu Zhang1, Xi Tang4, Dian Chen5, Xiao-Long Wang6, Guang Zeng7. 1. The First College of Clinical Medical Science, China Three Gorges University, Yichang 443003, China. 2. Oncology Institute, China Three Gorges University, Yichang 443003, China. 3. Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan 430071, China. 4. Department of Oncology, Jingzhou Central Hospital, Jingzhou 434020, China. 5. Department of Oncology, Central Hospital of Enshi Autonomous Prefecture, Enshi 445000, China. 6. Department of Urology, Research Lab/LIFE-Zentrum, University of Munich (LMU), München, Germany. 7. Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA.
Abstract
BACKGROUND: Evaluation of the clinical efficacy and safety of icotinib in advanced nonsquamous non-small cell lung cancer (NSCLC) patients with an unknown EGFR mutation who failed to respond to second-line chemotherapy. METHODS: Seventy-six cases of advanced nonsquamous NSCLC were involved in this study from seven hospitals from the Hubei province of China. Patients with an unknown EGFR mutation status were treated with Icotinib, at an oral dosage of 125 mg three times daily. All patients were followed up for at least 1 year to observe the efficacy, adverse reactions, and 1-year survival. RESULTS: The patients' overall objective response rate (ORR) was 34.2%, the disease control rate (DCR) was 75.0%, the clinical benefit rate (CBR) was 80.2%, the median progression-free survival (PFS) was 11.0 months, the median overall survival (OS) was 16.9 months, and the 1-year OS rate was 63.2%. Gender and smoking history were associated with the DCR (P<0.05). Both PFS and OS were significantly higher in groups that had pre-accepted ≤6 cycles of chemotherapy than in groups that had pre-accepted >6 cycles. CONCLUSIONS: Our results demonstrated that icotinib had a better DCR or clinical benefits for treating the patients with unknown EGFR mutation who failed to respond to second-line chemotherapy in advanced nonsquamous NSCLC, and the adverse effects are tolerable.
BACKGROUND: Evaluation of the clinical efficacy and safety of icotinib in advanced nonsquamous non-small cell lung cancer (NSCLC) patients with an unknown EGFR mutation who failed to respond to second-line chemotherapy. METHODS: Seventy-six cases of advanced nonsquamous NSCLC were involved in this study from seven hospitals from the Hubei province of China. Patients with an unknown EGFR mutation status were treated with Icotinib, at an oral dosage of 125 mg three times daily. All patients were followed up for at least 1 year to observe the efficacy, adverse reactions, and 1-year survival. RESULTS: The patients' overall objective response rate (ORR) was 34.2%, the disease control rate (DCR) was 75.0%, the clinical benefit rate (CBR) was 80.2%, the median progression-free survival (PFS) was 11.0 months, the median overall survival (OS) was 16.9 months, and the 1-year OS rate was 63.2%. Gender and smoking history were associated with the DCR (P<0.05). Both PFS and OS were significantly higher in groups that had pre-accepted ≤6 cycles of chemotherapy than in groups that had pre-accepted >6 cycles. CONCLUSIONS: Our results demonstrated that icotinib had a better DCR or clinical benefits for treating the patients with unknown EGFR mutation who failed to respond to second-line chemotherapy in advanced nonsquamous NSCLC, and the adverse effects are tolerable.
Authors: Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares Journal: Lancet Oncol Date: 2012-01-26 Impact factor: 41.316
Authors: Ji-Youn Han; Keunchil Park; Sang-We Kim; Dae Ho Lee; Hyae Young Kim; Heung Tae Kim; Myung Ju Ahn; Tak Yun; Jin Seok Ahn; Cheolwon Suh; Jung-Shin Lee; Sung Jin Yoon; Jong Hee Han; Jae Won Lee; Sook Jung Jo; Jin Soo Lee Journal: J Clin Oncol Date: 2012-02-27 Impact factor: 44.544
Authors: R Pirker; J R Pereira; A Szczesna; J von Pawel; M Krzakowski; R Ramlau; I Vynnychenko; K Park; W E E Eberhardt; F de Marinis; S Heeger; T Goddemeier; K J O'Byrne; U Gatzemeier Journal: Lung Cancer Date: 2012-04-11 Impact factor: 5.705
Authors: James Chih-Hsin Yang; Vera Hirsh; Martin Schuler; Nobuyuki Yamamoto; Kenneth J O'Byrne; Tony S K Mok; Victoria Zazulina; Mehdi Shahidi; Juliane Lungershausen; Dan Massey; Michael Palmer; Lecia V Sequist Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544
Authors: V Patil; V Noronha; A Joshi; Vamshi Muddu Krishna; S Juvekar; Gauri Pantvaidya; Pankaj Chaturvedi; D Chaukar; Supreeta Arya; Aswari Patil; B Bhosale; A Dongre; A K Dcruz; K Prabhash Journal: ISRN Oncol Date: 2013-09-11